Drug Information
Drug General Information | Top | |||
---|---|---|---|---|
Drug ID |
D0D3ZP
|
|||
Former ID |
DNC004857
|
|||
Drug Name |
NBI-42902
|
|||
Synonyms |
352290-60-9; UNII-3FWQ4MD98O; 3FWQ4MD98O; CHEMBL179691; NBI42902; GTPL1187; GTPL1178; SCHEMBL5758034; ZINC6716969; BDBM50162007; NBI 42902; API0005260; 2,4(1H,3H)-Pyrimidinedione, 3-((2R)-2-amino-2-phenylethyl)-1-((2,6-difluorophenyl)methyl)-5-(2-fluoro-3-methoxyphenyl)-6-methyl-; KB-138000; FT-0771447; 3-[(2R)-2-amino-2-phenylethyl]-1-[(2,6-difluorophenyl)methyl]-5-(2-fluoro-3-methoxyphenyl)-6-methylpyrimidine-2,4-dione
Click to Show/Hide
|
|||
Drug Type |
Small molecular drug
|
|||
Indication | Prostate cancer [ICD-11: 2C82.0; ICD-10: C61; ICD-9: 185] | Discontinued in Phase 1 | [1], [2] | |
Structure |
![]() |
Download2D MOL |
||
Formula |
C27H24F3N3O3
|
|||
Canonical SMILES |
CC1=C(C(=O)N(C(=O)N1CC2=C(C=CC=C2F)F)CC(C3=CC=CC=C3)N)C4=C(C(=CC=C4)OC)F
|
|||
InChI |
1S/C27H24F3N3O3/c1-16-24(18-10-6-13-23(36-2)25(18)30)26(34)33(15-22(31)17-8-4-3-5-9-17)27(35)32(16)14-19-20(28)11-7-12-21(19)29/h3-13,22H,14-15,31H2,1-2H3/t22-/m0/s1
|
|||
InChIKey |
CJUWBZDJMYYRDG-QFIPXVFZSA-N
|
|||
CAS Number |
CAS 352290-60-9
|
|||
PubChem Compound ID | ||||
PubChem Substance ID |
Target and Pathway | Top | |||
---|---|---|---|---|
Target(s) | Gonadotropin-releasing hormone receptor (GNRHR) | Target Info | Inhibitor | [3] |
KEGG Pathway | Neuroactive ligand-receptor interaction | |||
GnRH signaling pathway | ||||
NetPath Pathway | IL1 Signaling Pathway | |||
IL2 Signaling Pathway | ||||
Panther Pathway | Heterotrimeric G-protein signaling pathway-Gq alpha and Go alpha mediated pathway | |||
Reactome | Hormone ligand-binding receptors | |||
G alpha (q) signalling events | ||||
WikiPathways | Gastrin-CREB signalling pathway via PKC and MAPK | |||
Peptide GPCRs | ||||
GPCR ligand binding | ||||
GPCR downstream signaling | ||||
GPCRs, Other |
References | Top | |||
---|---|---|---|---|
REF 1 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 1178). | |||
REF 2 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800013539) | |||
REF 3 | Discovery of sodium R-(+)-4-{2-[5-(2-fluoro-3-methoxyphenyl)-3-(2-fluoro-6-[trifluoromethyl]benzyl)-4-methyl-2,6-dioxo-3,6-dihydro-2H-pyrimidin-1-yl]-1-phenylethylamino}butyrate (elagolix), a potent and orally available nonpeptide antagonist of the human gonadotropin-releasing hormone receptor. J Med Chem. 2008 Dec 11;51(23):7478-85. |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.